The Constitutive Expression of Type X Collagen in Mesenchymal Stem Cells from Osteoarthritis Patients Is Reproduced in a Rabbit Model of Osteoarthritis by Mwale, Fackson et al.
SAGE-Hindawi Access to Research
Journal of Tissue Engineering
Volume 2011, Article ID 587547, 10 pages
doi:10.4061/2011/587547
Research Article
The Constitutive Expression of Type X Collagen in Mesenchymal
Stem Cells from Osteoarthritis Patients Is Reproducedin a Rabbit
ModelofOsteoarthritis
Fackson Mwale,1,2 SoniaRampersad,2 H´ el` ene Richard,3 Yao Guoying,2 SoraAlRowas,2
Padma Madiraju,2 John Antoniou,1,2 and Sheila Laverty3
1Division of Orthopaedic Surgery, McGill University, Montreal, Quebec, Canada H3H 2P2
2Lady Davis Institute for Medical Research, SMBD—Jewish General Hospital, 3755 Chemin de la Cˆ ote Ste-Catherine,
Montreal, Quebec, Canada H3T 1E2
3Comparative Orthopaedic Research Laboratory, Faculty of Veterinary Medicine, University of Montreal, Saint Hyacinthe,
Quebec, Canada J2S 7C6
Correspondence should be addressed to Fackson Mwale, fmwale@ldi.jgh.mcgill.ca
Received 21 April 2011; Accepted 18 June 2011
Academic Editor: Alastair J. Sloan
Copyright © 2011 Fackson Mwale et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
The expression of type X collagen (COL X), a late-stage chondrocyte hypertrophy marker in human mesenchymal stem cells
(MSCs) from osteoarthritis (OA) patients poses a major setback to current cartilage and intervertebral disc tissue engineering
eﬀorts.However,itisnotyetclearwhetherCOLXisexpressedbyallhumanbonemarrowstemcellsorifitisrelatedtoage,gender,
site, disease status, or drug therapy. In the current study, we report that COL X expression is upregulated in MSCs from rabbits in
a surgical instability model of OA (anterior cruciate ligament transection (ACLT)) when compared to control rabbit MSCs. Thus
COL X expression in OA is a common phenomenon that is due to the disease process itself and not to other environmental factors.
It is, therefore, critical to understand MSC phenotype in OA patients, as these cells are essential clinically for biological repair of
cartilage lesions using autologous stem cells.
1.Introduction
Osteoarthritis (OA) is characterized by a slow degeneration
of articular cartilage and subchondral bone [1, 2]. At the
molecular level, degradation of type II collagen (COL II)
and proteoglycan components of the extracellular matrix
occurs resulting in a loss of both the tensile and compressive
strength of articular cartilage [1, 3, 4]. The incidence of OA
increases progressively with age [5] and is viewed as an age-
related dynamic reaction pattern of a joint in response to
insult or injury. Many authors have reported evidence for
chondrocyte diﬀerentiation in OA including proliferation,
cell cloning, expression of type X collagen (COL X) [6],an-
nexins and alkaline phosphatase, parathyroid-hormone-re-
lated peptide, matrix calciﬁcation, and apoptotic cell death
of the terminally diﬀerentiated chondrocytes. These cellular
changes are also observed in the growth platewhenthegrowth
cartilage is converted intobone(endochondralossiﬁcation)
[7].Inlinewiththeseﬁndings,werecentlyidentiﬁedcalcium
deposits and COL X in degenerative and scoliotic interverte-
bral discs (IVD), but not in control discs, and the level of the
indicatorsofcalciﬁcationpotentialwasconsistentlyhigherin
degenerative and scoliotic discs than in control discs [8]. If
the biological repair of cartilage and IVD is to become a real-
ity, calciﬁcation or subsequent bone formation of engineered
tissues has to be avoided.
COL X, a short-chain collagen was ﬁrst isolated from
chick hypertrophic chondrocytes and is a speciﬁc marker
for hypertrophic chondrocytes of the growth plate, the ﬁnal
stage before cartilage is converted to bone [9]. It is synthe-
sized and secreted prior to calciﬁcation and interacts with
ﬁbrils of COL II throughout the cartilage matrix [10]. It was2 Journal of Tissue Engineering
shown that COL X was also present in the zone of calciﬁed
cartilage of canine cartilage [11]. Furthermore, its synthesis
is upregulated by chondrocytes isolated from osteoarthritic
cartilage [6]. Osteoarthritic tissue has also been reported
to synthesize type I collagen (COL I) in the late stages of
degeneration [6, 12].
The clinical repair of articular cartilage lesions continues
to evolve. Most protocols address the treatment of full-
thickness (injuries that penetrate the subchondral bone plate
to the trabecular-bone spaces) rather than partial-thickness
defects (those that are conﬁned to the hyaline articular carti-
lage tissue alone). The reason for this is that partial-thickness
defects do not heal spontaneously whereas full-thickness
defects below a critical size can heal although transiently
[13, 14]. The strategies for repair of full-thickness cartilage
defects in humans or experimental animal models are
either tissue-based (entailing the grafting of perichondrial,
periosteal, cartilage, or bone-cartilage material) or cell-based
(utilizing chondrocytes, perichondrial cells or mesenchymal
stem cells (MSCs) with or without the assistance of a scaﬀold
matrix, with impregnated bioactive factors, to deliver the
cells.
Damaged articular cartilage has very little capacity for
spontaneous healing because of the avascular nature of the
tissue [15]. As an alternative to enhance repair, tissue engi-
neering has recently been reported [16, 17]. One treatment
option is autologous chondrocyte transplantation (ACT)
which is based on the isolation of chondrocytes from a
minor load-bearing area of the knee, cell expansion, and re-
transplantation as cell suspensions [18] or seeded into a
biodegradable scaﬀold before implantation [19, 20]. These
chondrocytes are usually from young animals. Employing
adult human chondrocytes for cartilage tissue engineering
in OA is invasive as it involves 2 surgeries, one to collect
and another to implant the construct. Furthermore, there
is no benign site for harvesting authentic autologous chon-
drocytes. It is also preferable to avoid the use of allogeneic
donor chondrocytes, as there is a potential risk of transfer-
ring infectious agents. Despite degenerative changes in the
host’s articular cartilage and a hostile inﬂammatory joint
environmentinOA,repairofcartilagetissuemaybepossible,
as the use of OA chondrocytes can generate a cartilage-like
matrix when grown on hyaluronic acid scaﬀolds, although
the cells signiﬁcantly synthesized less collagen than what was
generatedbychondrocytesfromindividualswithoutarthritis
[21].
Tissue engineering of cartilage using MSCs induced to
diﬀerentiate into a chondrocyte phenotype has been con-
sidered as an alternative treatment for cartilage degenera-
tion. Diﬀerentiation into chondrocytes ﬁrst appears to be
necessary for successful repair as MSCs directly implanted
into cartilage defects in animal models [22]r e s u l t e di na
ﬁbrocartilaginous repair. MSCs have been shown to undergo
chondrogenesis in vitro using a high-cell-density pellet cul-
ture system [23–25], which mimics the cellular condensation
requirements for embryonic mesenchymal chondrogenesis
and provides the physical and biochemical environmental
factors conducive to cartilage formation [24]. Treatment
with transforming growth factor-beta (TGF-β)s u p e r f a m i l y
members, TGF-β1[ 24, 26–29]o rT G F - β3[ 23, 25], and
dexamethasone (Dex) [24, 25, 30, 31] are key requirements
for the in vitro chondrogenic diﬀerentiation of MSCs. Other
growthfactors,suchasbasicﬁbroblastgrowthfactor(bFGF),
insulin-like growth factor-1 (IGF-1) [32], and parathyroid
hormone [33], have been found to enhance chondrogenesis.
We recently discovered that a major drawback of current
cartilage tissue engineering strategies is that human MSCs
harvestedfromOApatientsexpressCOLX[34–37],amarker
of late-stage chondrocyte hypertrophy [7, 38–40] that is usu-
ally implicated in endochondral ossiﬁcation and normally
absent from hyaline cartilage. The expression of this marker
in chondrocytes is considered to reﬂect an undesirable de-
generative phenotype. Reports that freshly isolated OA
chondrocytessynthesizepredominantlyCOLXwhilecontrol
chondrocytes from healthy cartilage synthesized mostly COL
II suggest focal premature chondrocyte diﬀerentiation to
hypertrophic cells in OA cartilage [6].
It was not clear whether our observations with COL
X message expression in OA MSCs were a universal phe-
nomenon with human bone marrow stem cells or whether
they are related to variables such as age, gender, site, disease
status (osteoarthritis/rheumatoid arthritis), or drug therapy.
Murphy et al. reported an altered phenotype in MSCs
isolated from OA patients [41]. They observed that their
proliferation rates were reduced, and diﬀerentiation proﬁle
was altered, and although chondrogenic and adipogenic
capacity was reduced, osteogenic capacity was augmented.
This enhanced osteogenesis would ﬁt with our gene expres-
sion proﬁle (COL X expression) in these cells. Furthermore,
she reported that these eﬀects were systemic and not only in
MSCs cultured from bone marrow at the OA site.
Animal models of OA provide an important opportunity
to address some of these issues [42, 43]. To date, there
have been no reports of studies in animal models of OA
examining thiscrucialquestion.Oneofthemostwidelyused
experimental models of OA is the anterior cruciate ligament
transection (ACLT) model that creates a joint instability and
progressive degeneration of the joint. The use of experi-
mental ACLT models is of particular clinical relevance, since
rupture of the ACL occurs in humans and also leads to the
development of OA [44]. Rabbit ACLT is increasingly being
used in OA studies [42, 43, 45, 46] because the disease onset
is rapid.
The objective of our study was to determine whether
the expression of COL X could be reproduced in MSCs
from rabbits in a standard rabbit ACLT model of OA. These
observations help provide more insight into the complex
interrelationships of the expression of COL X during OA.
2.MaterialsandMethods
2.1. Rabbit Experimental Model of Osteoarthritis. Fifteen
skeletally mature (9-month-old) female New Zealand white
rabbits (Charles River, Saint Constant, QC, Canada) weigh-
ing a mean ± SD of 4.28 ± 0.39kg were employed in
this experiment. Radiographs of both femorotibial joints
were taken to exclude animals with joint pathology at the
study outset. 5 unoperated rabbits served as controls, andJournal of Tissue Engineering 3
Table 1: Scores employed for macroscopic articular cartilage changes.
Score Structure Length of the lesion
1 Intact surface: surface normal
in appearance and does not retain India ink
2F i s s u r e s 0 m m t o ≤4mm
3 Fissures >4m mt o≤8mm
4 Fissures >8mm
5 Full-depth erosion 0mm to ≤2mm
6F u l l - d e p t h e r o s i o n > 2mmto≤5mm
7F u l l - d e p t h e r o s i o n >5mm
the remaining 10 underwent unilateral ACLT under general
anesthesia as described previously with some minor modiﬁ-
cations [47]. The animals in this study were part of another
larger unrelated study. The Institutional Animal Care and
Use Committee of the Faculty of Veterinary Medicine,
University of Montreal, approved all the procedures.
2.2. Surgical Procedure. T h es u r g e r yw a sp e r f o r m e db ya
board-certiﬁed veterinary surgeon under sterile conditions.
Trimethoprim-sulfamide (Tribissen 24%, Schering-Plough
Animal Health, Pointe Claire, QC, Canada), 15mg/kg SC,
was administered immediately preoperatively. Rabbits were
thenpremedicated,andanesthesiawasinducedwithxylazine
(Novopharm Limited, Animal Health, Toronto, Canada)
3mg/kg, IM glycopyrrolate (Sabex Inc, QC, Canada)
0.01mg/kg IM, and ketamine (Bioniche, Animal Health
Canada Inc.) 17mg/kg IM. Anesthesia was maintained with
2–2.75% isoﬂurane (Baxter Corporation, Mississauga, ON,
Canada) via an orotracheal tube.
The left ACL was exposed by a medial parapatellar skin
incision, the patella was subluxated laterally, and the knee
was placed in full ﬂexion. The anterior cruciate ligament
was transected, and the incision was sutured in a routine
manner. Analgesia was achieved with the administration
of buprenorphine (Schering-Plough Ltd, Welwyn Garden
City, UK) 0.03mg/kg SC, preoperatively and 12 hours
later. Fentanyl (Novo-Fentanyl 25, Fentanyl Transdermal
System, Novopharm, Markham, ON, Canada), 25μg/hour,
was applied to the lumbar region for 72 hours. Following
surgery, rabbits were housed separately and permitted free
cage activity until the termination of the study.
2.3. Postmortem Harvest of Bone Marrow Aspirate. Animals
were humanely euthanized 12 weeks after surgery. Bone
marrow aspirates were aseptically harvested from the distal
femur, following transection, by injecting DMEM with a
syringe, followed by aspiration of the bone marrow similar
tomethodsdescribedpreviously[48].Thesampleswerethen
transported to the laboratory for separation and culture.
2.4. Macroscopic Cartilage Assessment. Both femur compart-
ments (medial femoral condyle (MFC) and lateral femoral
condyle (LFC)) were assessed for the extent of gross mor-
phologic changes of the articular cartilage surface including
ﬁbrillation and ulceration of cartilage that are characteristic
features of OA. The mean score of both compartments
represented a femur macroscopic score that reﬂected the
disease burden at the articular surface (ranging from 1
for a normal joint surface to 7 with very severe disease).
Details of the score attribution are provided in Table 1 [42].
Scoring was performed after the application of Indian ink
that highlights areas of ﬁbrillation.
2.5. Histological Assessment of Cartilage. Femoral articular
surfaces were ﬁxed in 10% neutral buﬀered formalin. Tissue
blocks were decalciﬁed with 20% EDTA (Fisher Scientiﬁc,
Nepean, ON, Canada) in 10mM phosphate buﬀer (pH
7.4), dehydrated through graded alcohols, cleared with
100% toluol, and embedded in paraﬃn. Following paraﬃn
embedding,5μmsectionswerecutfromthearticularsurface
(through the most severe lesion observed macroscopically)
and stained with Safranin O/fast green. Histological sections
were obtained from each of the femur compartments
described above. The histologic sections from each site
were evaluated using a modiﬁed Mankin’s grading system
illustrated in Table 3 [42, 47]. The mean histological score
from both compartments represented the femur cartilage
pathology score.
2.6. MSC Culture. Bone marrow aspirates were processed,
and MSCs were cultured as previously described [34].
Brieﬂy, each aspirate was transferred to a 50mL sterile tube
and diluted 1:1 with Dulbecco’s modiﬁed eagle medium
(DMEM; Hyclone, Chateauguay, QC) supplemented with
100units/mLpenicillinand100μg/mLstreptomycin(1%PS;
Hyclone). The tube was centrifuged at 600 ×g for 10 min-
utes. After two washes, the cells were resuspended in 20mL
MSC complete medium (DMEM supplemented with 10%
fetal bovine serum (FBS; Hyclone) and 1% PS and cultured
underpreconﬂuentmonolayerconditionsin150mmculture
dishes, at 37◦C with 5% humidiﬁed CO2. After 72 hours,
nonadherent cells were discarded, and the adherent ones
were thoroughly washed twice with DMEM (low glucose)
and cultured for 2 passages in DMEM (low glucose) supple-
mented with 10% fetal bovine serum, 100U/mL penicillin,
and 100ug/mL streptomycin as described previously [34].4 Journal of Tissue Engineering
Table 2: Primers used for PCR ampliﬁcation.
Gene Primer sequence Size (bp)
COL I Forward: CGGTTACCCTGGCAATATTG
Reverse: TCCAGTGCGACCATCTTT
116
COL X Forward: ACAGGAATGCCTGTGTCTGCTTTACT
Reverse: CATTGGGAAGCTGGAGCCACACCTGGTC
331
GAPDH Forward: GCTCTCCAGAACATCATCCCTGCC
Reverse: CGTTGTCATACCAGGAAATGAGCTT
346
Table 3: Histochemical/histological assessment of the articular cartilage changes in the rabbit model of osteoarthritis.
Safranin O—fast green staining
0 = uniform staining throughout articular cartilage
1 = loss of staining in superﬁcial zone of hyaline cartilage ≤50% the length of the condyle or plateau
2 = loss of staining in superﬁcial zone of hyaline cartilage ≥50% the length of the condyle or plateau
3 = loss of staining in the upper 2/3s of hyaline cartilage ≤50% the length of the condyle or plateau
4 = loss of staining in the in the upper 2/3s hyaline cartilage ≥50% the length of the condyle or
plateau
5 = loss of staining in all the hyaline cartilage ≤50% the length of the condyle or plateau
6 = loss of staining in all the hyaline cartilage ≥50% the length of the condyle or plateau
Structure
0 = normal
1 = surface irregularities
2 = ﬁssures in ≤50% surface
3 = ﬁssures in ≥50% surface
4 = erosion 1/3 hyaline cartilage ≤50% surface
5 = erosion 1/3 hyaline cartilage ≥50% surface
6 = erosion 2/3 hyaline cartilage ≤50% surface
7 = erosion 2/3 hyaline cartilage ≥50% surface
8 = full-depth erosion hyaline cartilage ≤50% surface
9 = full-depth erosion hyaline cartilage ≥50% surface
10 = full-depth erosion hyaline and calciﬁed cartilage to the subchondral bone ≤50% surface
11 = full-depth erosion hyaline and calciﬁed cartilage to the subchondral bone ≥50% surface
Chondrocyte density
0 = no decrease in cells
1 = focal decrease in cells
2 = multifocal decrease in cells
3 = multifocal conﬂuent decrease in cells
4 = diﬀuse decrease in cells
Cluster formation
0 = normal
1 = <4c l u s t e r s
2 = ≥4b u t< 8c l u s t e r s
3 = ≥8c l u s t e r s
2.7.GeneExpression. PelletsweredigestedwithproteinaseK,
and total RNA was extracted using Trizol (Invitrogen).
Reverse transcription reaction was performed using Super-
script II RNase H-RT (Invitrogen) and then ampliﬁed by
PCR using gene-speciﬁc primers for COL I and COL X
(Table 2). Relative gene expression with reference to GAPDH
was determined and expressed as before [37]. PCR products
were visualized by ethidium bromide staining on 2% agarose
gels.
2.8. Statistical Analysis. A Wilcoxon-signed rank test was
employed to assess diﬀerences in the femoral articular carti-
lage macroscopic and histological scores between ACLT and
control groups of animals. An analysis of variance (ANOVA)
followed by Fisher’s protected least signiﬁcant diﬀerence
(PLSD) post hoc test using Stat view (SAS Institute Inc.,
Cary, NC) was employed to assess gene expression. Results
are presented as the mean ± standard deviation. Diﬀerences
were considered statistically signiﬁcant at P<0.05.Journal of Tissue Engineering 5
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Figure 1: Macroscopic articular cartilage lesions of the distal femur observed in the rabbits. (a) Intact cartilage surface, (b) ﬁbrillation
(enhanced uptake of ink between arrows), (c) complete ulceration of cartilage (between the arrows) on the femoral condyle. (d) The mean
femur cartilage macroscopic score reﬂecting the disease burden in the control and OA (ACLT) joints. ∗Indicates P<0.05. One animal was
deleted from each group to give n = 4 in the control group and n = 9 in the ACLT group because of problems encountered with cell culture
from these animals (see methods).
3. Results
3.1. Macroscopic and Histologic Assessment of Articular
Cartilage. Postmortem inspection revealed that ACLT was
complete in all rabbits included in the study. Macroscopic
cartilage scores are illustrated in Figure 1. In the control
rabbitjoints(Figure 1(a)),themeanfemurarticularcartilage
macroscopic grade was 1. In the ACLT rabbit joints (Figures
1(b) and 1(c)), the mean femur articular cartilage macro-
scopic score was signiﬁcantly increased (Figure 1(d)) when
compared to the control joints.
Histological scores and representative lesions are pre-
sented in Figure 2. In the OA group, the induced OA lesions
(ﬁbrillation and erosion of articular cartilage) were focal
and occurred at the same sites in all ACL-transected joints
(Figures 2(b), 2(c) and 2(d)). Typical ﬁbrillation and erosion
of the articular cartilage, hallmarks of OA, were observed
in the ACLT joints but not in the control joints (Figure 2).
The mean femur articular cartilage histological score was
signiﬁcantly higher in the ACLT animals when compared to
the controls.
3.2. MSC Culture. Marrow aspirates were obtained from 5
control and 10 operated groups. One sample from each
groupwaseliminatedbecausenocellsattachedafter72hours
in culture, giving a total of n = 4c o n t r o l sa n dn = 9
ACLT animals. MSCs were successfully expanded from the
remaining aspirates forming colonies in primary culture
thatwerecharacteristicallyspindle-shapedwithaﬁbroblastic
morphology (data not shown). MSCs from ACLT animals6 Journal of Tissue Engineering
0.1mm
(a)
0.1mm
(b)
0.1mm
(c)
0.1mm
(d)
14
12
10
8
6
4
2
0
N = 4 N = 9
M
e
a
n
f
e
m
u
r
c
a
r
t
i
l
a
g
e
h
i
s
t
o
l
o
g
i
c
a
l
s
c
o
r
e
∗
Control
ACLT
(e)
Figure 2:Safranin-O-stainedsectionsfromthedistalfemurillustratingrepresentativeOAlesionsinthismodel.(a)Intactarticularcartilage,
(b) ﬁssures of the articular cartilage with some loss of Safranin O stain from the surface, (c) extensive loss of Safranin O stain, Focal
chondrocyte cloning, (d) complete erosion of the hyaline cartilage, (e) the mean femur cartilage histological score reﬂecting the disease
burden in the control and OA (ACLT) joints. ∗Indicates P<0.05. One animal was deleted from each group to give n = 4 in the control
group and n = 9 in the ACLT group because of problems encountered with cell culture from these animals (see methods).Journal of Tissue Engineering 7
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Figure 3: Expression of COL X mRNA and COL I mRNA in MSCs from experimental OA rabbits. COL I mRNA level did not vary
signiﬁcantly in both groups of rabbits. Expression of COL X was enhanced in MSCs from OA rabbits. ∗Signiﬁes P<0.05.
were morphologically indistinguishable from the cultures of
normalcontrols,andthecellyieldwascomparableattheend
of primary cultures.
3.3. Eﬀect of OA on Collagen Gene Expression. Message ex-
pression for COL I and COL X genes was analyzed after cul-
turing MSCs from control or the experimental OA rabbits.
After culturing the cells for 7 days, MSCs from normal
rabbits show weak COL X message (Figure 3). Of special
interest here was that OA led to an increase in COL X
expression (Figure 3). COL I message is present in MSCs
from normal and OA rabbits and did not vary signiﬁcantly
in both groups of rabbits. COL II was not expressed, and OA
had no eﬀect on its expression (data not shown).
4. Discussion
This study was conducted to determine whether the expres-
sion of COL X could be reproduced in MSCs from rabbits
in a standard rabbit ACLT model of OA. In recent years,
surgically induced instability models of OA are frequently
usedtoassessthetherapeuticeﬃcacyofcompoundstargeted
for OA treatment, because the procedure induces cartilage
lesions similar to those observed in humans with OA [46, 49,
50]. The ACLT is a reproducible and eﬀective model of OA
[49]. The cartilage lesions in this model, and their response
totherapycanbegradedaccordingtoanadaptedhistological
and histochemical grading system [42].
We showed that human MSCs from OA patients express
COL X [34–37]. Our attempts to investigate whether the
expression of COL X can be reproduced in MSCs from
rabbitsinasurgicalinstabilitymodelofOAusingestablished
methodology clearly revealed that OA upregulates COL X
expression in MSCs. These observations are contrary to what
one wouldexpect,asCOL X is onlysupposed to be expressed
by chondrocytes when they become hypertrophic [40, 51,
52]. It is tempting to suggest that COL X may play a role in
the bone marrow stromal microenvironment, as mice deﬁ-
cient in COL X show defects in hematopoiesis [53].
The present study suggests that the expression of COL X
in OA is a universal phenomenon that is due to the disease
process itself and not other environmental factors. Results of
the present study show for the ﬁrst time that OA modulates
the expression of COL X expression. In this system, COL X
message expression may not be a good marker for chondro-
cyte hypertrophy during early MSC diﬀerentiation.
It is possible that COL X has a serendipitous expression
but with no functional consequence. However, we have
shown that MSCs from OA patients express not only COL
X but also osteogenic diﬀerentiation markers such as al-
kaline phosphatase, bone sialoprotein, osteocalcin, and the
transcription factor RUNX2 [36, 37]. Therefore, the risk
of calciﬁcation and subsequent bone formation in cartilage
repair is real. Previously we have shown that COL I but not
COL II is expressed by MSCs from OA patients [34, 37].
Similar ﬁndings were observed in this study.8 Journal of Tissue Engineering
Other factors such as age, gender, or drug therapy [54]
may still have an inﬂuence on the ability of MSCs to
diﬀerentiate. Finding ways to suppress this expression of
COLXisimportantforfuturetissueengineeringstrategiesto
succeed in OA patients [33, 36, 37, 55, 56]. The sites assessed
were adjacent to the injury so we suspect that the injury
environment altered their gene expression. An additional
issue, worth exploring, would be whether MSCs, remote
from the site of injury, in other bones could also have this
altered expression (a systemic eﬀect) as previously observed
by Murphy et al. [41]. Equally, although less plausible, the
MSCswithalteredCOLXexpressionmayrepresentcellsthat
have homed to these sites. The latter hypothesis is unlikely as
these were young adult rabbits, and it would be surprising if
they did not have an ample population of stem cells locally
at the site of injury, but this also requires conﬁrmation.
An additional area of future study, related to the ﬁndings
reported herein, would be the eﬀect of OA on MSC chondro-
genesis.Previouslyitwasshownthatthesecellshadareduced
proliferative capacity, chondrogenic and adipogenic activity
compared with that in normal cultures although the CFU-F
formationcapacitywassimilar[41].Ourstudiesshowedthat
MSCs from OA patients cultured in deﬁned chondrogenic
medium supplemented with transforming growth factor
(TGF-) β1o rβ3 and dexamethazone expressed aggrecan
constitutively, and COL X was expressed before COL II [34].
Although we did not analyze the surface markers on
these cells, MSCs from OA patients stained strongly for
CD90 (Thy-1), and they were mildly to highly positive for
CD73 and CD44 (HCAM), three markers of MSCs [56].
The observed wide range depended upon the particular
donors. The expression range for CD73 extended from 52%
to 100%, with the median at 94%. CD44 expression range
was from 11% to 100%, with the median at 65%. Cells
stained predominantly negatively for CD34 and CD45, two
markers of hematopoietic stem cells. Further studies are,
however, necessary to better understand the eﬀect of OA on
chondrocyte hypertrophy.
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